OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

EARNINGS CALL ARCHIVE 4 CALLS ON FILE

RIGL — Rigel Pharmaceuticals, Inc.

NASDAQ

FULL STOCK PAGE →

Q4 2025 Earnings Call Summary

MAR 3, 2026

REVENUE

$69.8M +0.5%

NET MARGIN

384.0% +343.9 PTS

EPS

$14.72 +849.7%

FREE CASH FLOW

$22.0M -8.4%

No summary has been written for this call yet.